Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -8.00
- Piotroski Score 2.00
- Grade Buy
- Symbol (APM)
- Company Aptorum Group Limited
- Price $1.69
- Changes Percentage (-0.89%)
- Change -$0.02
- Day Low $1.63
- Day High $1.80
- Year High $17.49
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 12/20/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.62
- Trailing P/E Ratio -7.1
- Forward P/E Ratio -7.1
- P/E Growth -7.1
- Net Income $-2,824,647
Income Statement
Quarterly
Annual
Latest News of APM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Matt Chapman wins Giants' Willie Mac Award: 'I just feel like I'm being myself'
Matt Chapman had an outstanding month, signing a lucrative contract, welcoming a child, and receiving the Willie Mac Award for leadership. He aims to lead the Giants to the postseason next year and co...
By The New York Times | 2 weeks ago -
APM Automotive Holdings Berhad's (KLSE:APM) Returns Have Hit A Wall
To identify stocks with long-term growth potential, focus on increasing ROCE and expanding capital employed. APM Automotive Holdings Berhad has a ROCE of 6.0%, lower than the industry average of 11%, ...
By Yahoo! Finance | 2 weeks ago -
China's Leapmotor and Stellantis open orders in Europe for budget EVs
MILAN (Reuters) - China's Leapmotor is set to start taking orders in Europe for a city car and an SUV, the automaker and its partner Stellantis said on Tuesday as they expand their budget electric...
By Reuters | 2 weeks ago
